Overexpression of aldo‐keto reductase 1C2 is associated with disease progression in patients with prostatic cancer

Huang K‐H, Chiou S‐H, Chow K‐C, Lin T‐Y, Chang H‐W, Chiang I‐P & Lee M‐C
(2010) Histopathology 57, 384–394
Overexpression of aldo‐keto reductase 1C2 is associated with disease progression in patients with prostatic cancer

[1]  L. Kauvar,et al.  Importance of glutathione and associated enzymes in drug response. , 1997, Oncology research.

[2]  Liang-Shun Wang,et al.  Inverse expression of dihydrodiol dehydrogenase and glutathione‐S‐transferase in patients with esophageal squamous cell carcinoma , 2004, International journal of cancer.

[3]  A. Simoneau.  Treatment- and disease-related complications of prostate cancer. , 2006, Reviews in urology.

[4]  K. Chow,et al.  Increased Expression of Dihydrodiol Dehydrogenase Induces Resistance to Cisplatin in Human Ovarian Carcinoma Cells* , 2002, The Journal of Biological Chemistry.

[5]  Tzei-Yi Lin,et al.  Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung cancer. , 2001, Cancer research.

[6]  P. Walsh,et al.  Association of cigarette smoking with extraprostatic prostate cancer in young men. , 2003, The Journal of urology.

[7]  J. Simons,et al.  Interleukin-6: a candidate mediator of human prostate cancer morbidity. , 1995, Urology.

[8]  L. A. Plaskon,et al.  Cigarette smoking and risk of prostate cancer in middle-aged men. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[9]  H. Lou,et al.  Induction of AKR1C2 by Phase II Inducers: Identification of a Distal Consensus Antioxidant Response Element Regulated by NRF2 , 2006, Molecular Pharmacology.

[10]  Jeonga Kim,et al.  Sodium butyrate regulates androgen receptor expression and cell cycle arrest in human prostate cancer cells. , 2007, Anticancer research.

[11]  Y. Hung,et al.  Infection of human papillomavirus and overexpression of dihydrodiol dehydrogenase in uterine cervical cancer. , 2006, Gynecologic oncology.

[12]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[13]  John T. Wei,et al.  Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression , 2009, Nature.

[14]  S. Coughlin,et al.  Cigarette smoking as a predictor of death from prostate cancer in 348,874 men screened for the Multiple Risk Factor Intervention Trial. , 1996, American journal of epidemiology.

[15]  Ming-Chih Chou,et al.  Overexpression of aldo-keto reductase 1C2 as a high-risk factor in bladder cancer. , 2007, Oncology reports.

[16]  S. Chiang,et al.  Cigarette smoking induces overexpression of hepatocyte growth factor in type II pneumocytes and lung cancer cells. , 2006, American Journal of Respiratory Cell and Molecular Biology.

[17]  W. Remmele,et al.  Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs. subjective grading (IRS). , 1993, Pathology, research and practice.

[18]  Michael E. Burczynski,et al.  Human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1–AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones , 2000 .

[19]  Y. Chiang.  Hepatocyte growth factor induces hypoxia‐related interleukin‐8 expression in lung adenocarcinoma cells , 2009, Molecular carcinogenesis.

[20]  S. Kuo,et al.  Expression spectra of matrix metalloproteinases in metastatic non-small cell lung cancer. , 2004, Oncology reports.

[21]  M. Tsai,et al.  The elevated serum interleukin-6 correlates with the increased serum butyrate level in patients with nasopharyngeal carcinoma. , 2003, Oncology reports.

[22]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[23]  K. Chow,et al.  Genetic polymorphism and gene expression of microsomal epoxide hydrolase in non-small cell lung cancer. , 2007, Oncology reports.

[24]  Qing Yang,et al.  AKR1C2 and AKR1C3 mediated prostaglandin D2 metabolism augments the PI3K/Akt proliferative signaling pathway in human prostate cancer cells , 2008, Molecular and Cellular Endocrinology.

[25]  Jianfeng Xu,et al.  Inflammation in prostate carcinogenesis , 2007, Nature Reviews Cancer.

[26]  E. Maser,et al.  Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction. , 2000, Biochemical pharmacology.

[27]  T. Penning,et al.  Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. , 1999, Cancer research.

[28]  D. Peehl,et al.  Human type 3 3alpha-hydroxysteroid dehydrogenase (aldo-keto reductase 1C2) and androgen metabolism in prostate cells. , 2003, Endocrinology.

[29]  Kuang-Tai Kuo,et al.  Reversal of inflammation‐associated dihydrodiol dehydrogenases (AKR1C1 and AKR1C2) overexpression and drug resistance in nonsmall cell lung cancer cells by wogonin and chrysin , 2007, International journal of cancer.